The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition

Amyloid. 2019;26(sup1):39-40. doi: 10.1080/13506129.2019.1593133.

Authors

Jonas Wixner¹, Per Westermark², Elisabet Ihse², Björn Pilebro¹, Hans-Erik Lundgren¹, Intissar Anan¹

Affiliations

¹ a Department of Public Health and Clinical Medicine, Umeå University , Umeå , Sweden.
² b Department of Immunology Genetics and Pathology, Uppsala University , Uppsala , Sweden.

PMID: 31343354
DOI: 10.1080/13506129.2019.1593133

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Aged
Aged, 80 and over
Amyloid / drug effects
Amyloid Neuropathies, Familial / drug therapy*
Amyloid Neuropathies, Familial / genetics
Amyloid Neuropathies, Familial / pathology
Diflunisal / administration & dosage*
Diflunisal / adverse effects
Drug-Related Side Effects and Adverse Reactions / classification
Drug-Related Side Effects and Adverse Reactions / pathology
Female
Humans
Male
Middle Aged
Mutation
Prealbumin / genetics*
Sweden / epidemiology

Substances

Amyloid
Prealbumin
Diflunisal

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related